14:41:21 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-27 Bokslutskommuniké 2024
2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 X-dag ordinarie utdelning COEGIN 0.00 SEK
2024-05-23 Kvartalsrapport 2024-Q1
2024-05-23 Årsstämma
2024-02-29 Bokslutskommuniké 2023
2024-02-05 Extra Bolagsstämma 2024
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-06-15 Split COEGIN 100:1
2023-05-26 X-dag ordinarie utdelning COEGIN 0.00 SEK
2023-05-25 Årsstämma
2023-05-25 Kvartalsrapport 2023-Q1
2023-02-27 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-20 X-dag ordinarie utdelning COEGIN 0.00 SEK
2022-05-19 Kvartalsrapport 2022-Q1
2022-05-19 Årsstämma
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-27 Årsstämma
2021-05-21 X-dag ordinarie utdelning COEGIN 0.00 SEK
2021-05-20 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-09-29 Extra Bolagsstämma 2020
2020-08-28 Kvartalsrapport 2020-Q2
2020-04-15 Inlösen COEGIN 0.1
2020-04-03 X-dag ordinarie utdelning COEGIN 0.00 SEK
2020-04-02 Årsstämma
2020-02-21 Bokslutskommuniké 2019
2019-11-23 Kvartalsrapport 2019-Q3
2019-09-09 Extra Bolagsstämma 2019
2019-08-24 Kvartalsrapport 2019-Q2
2019-06-18 X-dag ordinarie utdelning COEGIN 0.00 SEK
2019-06-17 Årsstämma
2019-03-16 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-08-24 Kvartalsrapport 2018-Q2
2018-06-20 Årsstämma
2018-06-07 X-dag ordinarie utdelning COEGIN 0.00 SEK
2018-02-23 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriBioteknik
Coegin Pharma är ett svenskt bioteknikföretag med dermakosmetiska projekt för hårtillväxt och hudpigmentering, samt läkemedelskandidater för behandling av hjärtinfarkt och leukemi. Gemensamt för projekten är att de har sin grund i patenterade teknologiplattformar och samarbeten med forskare och akademiker internationellt. Coegin Pharma har sitt huvudkontor i Lund.
2024-09-16 08:45:00

Coegin Pharma has agreed on subscription commitments totalling approx. MSEK 9.8 concerning warrants of series TO3 ("TO3"). The subscription commitments have been made by a group of the company's larger shareholders and correspond to approximately 47 % of the proceeds the company may receive through the exercise of all TO3 warrants.

In connection with the rights issue carried out at the beginning of 2024, a total of 5,279,936 TO3 were issued. Each warrant entitles the holder to subscribe for one new share in Coegin Pharma at a subscription price of SEK 3.90 per share. Subscription with the support of TO3 can take place during the period from 16 September 2024 to 30 September 2024. If all TO3 warrants are exercised for share subscription, the company will receive approximately MSEK 20.6 before issue costs.

Coegin Pharma has received subscription commitments from the following warrant holders:

Subscribers

Commitment (SEK)

Quarterback Capital AB

2,000,000

Alveco Invest AB

1,751,381

Crystallus AB

1,083,330

Lennart Börjesson

1,000,000

Rune Löderup (privat och genom bolag)

1,000,000

Wilhelm Svenstig AB

1,000,000

Urban Engström

722,222

Bengt Svenstig

361,109

RW-Leasing Aktiebolag

361,109

Br Börjessons Bil AB:s Pensionsstiftelse

300,000

Mathias Rasteby

200,000

Totalt:

9,779,151


The subscription commitments are not secured by a bank guarantee, escrow, pledging, or similar arrangements. No compensation is provided for the subscription commitments.

"We are very pleased with the long-term commitment shown by our major shareholders through these subscription commitments. Their support is a clear testament to their confidence in our future and provides us with the stability we need to continue our launch preparations for our hair growth project FOL005," says Jens Eriksson, CEO of Coegin Pharma.

The full terms of TO3 and the relevant investment memorandum published by Coegin Pharma on 6 February 2024, are available on the company's website, coeginpharma.com.

For further information, please contact:
Jens Eriksson, CEO
Email: info@coeginpharma.com
Phone: +46 72 221 24 21

This information is information that Coegin Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication, through the agency of the contact person set out above, at 08:45 CET on 16 September 2024.

This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.

About Coegin Pharma
Coegin Pharma is a Swedish biotech company with dermacosmetic innovations for hair growth and skin pigmentation, alongside groundbreaking drug candidates for the treatment of myocardial infarction and leukemia. Coegin is planning for the launch of its first product series for hair growth in 2025, followed by a skin pigmentation product in 2026. 

Coegin Pharma's shares are listed on NGM Nordic SME and Börse Stuttgart, and the company has a registered office in Lund, Sweden. 

For more information, please visit: coeginpharma.com/en